BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26976426)

  • 1. Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
    Schmid P; Pinder SE; Wheatley D; Macaskill J; Zammit C; Hu J; Price R; Bundred N; Hadad S; Shia A; Sarker SJ; Lim L; Gazinska P; Woodman N; Korbie D; Trau M; Mainwaring P; Gendreau S; Lackner MR; Derynck M; Wilson TR; Butler H; Earl G; Parker P; Purushotham A; Thompson A
    J Clin Oncol; 2016 Jun; 34(17):1987-94. PubMed ID: 26976426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
    Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
    Kaufman B; Mackey JR; Clemens MR; Bapsy PP; Vaid A; Wardley A; Tjulandin S; Jahn M; Lehle M; Feyereislova A; Révil C; Jones A
    J Clin Oncol; 2009 Nov; 27(33):5529-37. PubMed ID: 19786670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
    Ma CX; Suman VJ; Sanati S; Vij K; Anurag M; Leitch AM; Unzeitig GW; Hoog J; Fernandez-Martinez A; Fan C; Gibbs RA; Watson MA; Dockter TJ; Hahn O; Guenther JM; Caudle A; Crouch E; Tiersten A; Mita M; Razaq W; Hieken TJ; Wang Y; Rimawi MF; Weiss A; Winer EP; Hunt KK; Perou CM; Ellis MJ; Partridge AH; Carey LA
    JAMA Oncol; 2024 Mar; 10(3):362-371. PubMed ID: 38236590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
    Smith IE; Walsh G; Skene A; Llombart A; Mayordomo JI; Detre S; Salter J; Clark E; Magill P; Dowsett M
    J Clin Oncol; 2007 Sep; 25(25):3816-22. PubMed ID: 17679728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
    Polychronis A; Sinnett HD; Hadjiminas D; Singhal H; Mansi JL; Shivapatham D; Shousha S; Jiang J; Peston D; Barrett N; Vigushin D; Morrison K; Beresford E; Ali S; Slade MJ; Coombes RC
    Lancet Oncol; 2005 Jun; 6(6):383-91. PubMed ID: 15925816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Vuylsteke P; Huizing M; Petrakova K; Roylance R; Laing R; Chan S; Abell F; Gendreau S; Rooney I; Apt D; Zhou J; Singel S; Fehrenbacher L
    Ann Oncol; 2016 Nov; 27(11):2059-2066. PubMed ID: 27573562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
    Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
    Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
    Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
    J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
    Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A;
    Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
    J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
    Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
    Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
    Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
    J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
    Semiglazov VF; Semiglazov VV; Dashyan GA; Ziltsova EK; Ivanov VG; Bozhok AA; Melnikova OA; Paltuev RM; Kletzel A; Berstein LM
    Cancer; 2007 Jul; 110(2):244-54. PubMed ID: 17538978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
    Bergh J; Jönsson PE; Lidbrink EK; Trudeau M; Eiermann W; Brattström D; Lindemann JP; Wiklund F; Henriksson R
    J Clin Oncol; 2012 Jun; 30(16):1919-25. PubMed ID: 22370325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
    Carlson RW; O'Neill A; Vidaurre T; Gomez HL; Badve SS; Sledge GW
    Breast Cancer Res Treat; 2012 Jun; 133(3):1049-56. PubMed ID: 22418699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.